Today: 28 February 2026
Subscribe
Browse Category

NYSE:NVS 11 August 2025 - 8 February 2026

Novartis share price sits near a 52-week high after San Diego research build — what investors watch next

Novartis share price sits near a 52-week high after San Diego research build — what investors watch next

Novartis shares closed up 0.57% at CHF 119.96 in Zurich on Friday, hitting a 52-week high of CHF 120.64. The company broke ground on a 466,000-square-foot research center in San Diego, set to open in 2029. Investors await the March 6 shareholder meeting and March 10 ex-dividend date. Novartis forecasts a low single-digit decline in 2026 adjusted operating profit due to patent expiries.
8 February 2026
··
Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

Novartis shares closed up 0.6% in Zurich at 119.96 francs Friday, with U.S. ADRs gaining 1.5%. The company broke ground on a new San Diego research center and reported a positive draft reimbursement recommendation for Kisqali in Canada. Investors are watching for the March 6 annual meeting and March 10 ex-dividend date tied to a proposed 3.70-franc payout.
7 February 2026
···
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Salesforce (CRM) Stock After Hours Today (Dec. 17, 2025): Qualified Acquisition, Novartis Agentforce Deal, Analyst Forecasts, and What to Watch Before the Market Opens

Salesforce (CRM) Stock After Hours Today (Dec. 17, 2025): Qualified Acquisition, Novartis Agentforce Deal, Analyst Forecasts, and What to Watch Before the Market Opens

Salesforce closed Wednesday at $258.14, up 1.27%, then slipped to about $257.50 after hours. Novartis announced a five-year global rollout of Salesforce’s Agentforce Life Sciences platform. After the bell, Salesforce said it will acquire Qualified, an AI marketing firm, with terms undisclosed. BTIG initiated coverage on Salesforce with a Buy rating.
18 December 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis will acquire Avidity Biosciences for $12 billion in cash, offering $72 per share—a 46% premium over Avidity’s last close. Avidity’s stock, which ended Friday at $49.15, is expected to jump sharply when markets open. Novartis is targeting Avidity’s RNA therapies for rare muscle diseases, including a lead drug nearing FDA submission. The deal was announced Sunday, Oct. 26, 2025.
26 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Undersea Cable Chaos, iPhone 17 “Air” Reveal & $500B Cloud Bombshell – The Biggest Tech News (Sept 9–10, 2025)

Undersea Cable Chaos, iPhone 17 “Air” Reveal & $500B Cloud Bombshell – The Biggest Tech News (Sept 9–10, 2025)

Apple launched its iPhone 17 lineup, debuting the 5.6 mm-thin iPhone 17 Air at $999 and updating AirPods Pro and Apple Watch models, with prices mostly unchanged. Multiple undersea internet cables were cut in the Red Sea, disrupting service from Asia to East Africa; Microsoft warned Azure users of increased latency. U.S. prosecutors indicted a Ukrainian hacker linked to global ransomware attacks, offering an $11 million reward for his capture.
10 September 2025
·······
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···
Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

The FDA approved brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis, affecting about 500,000 Americans. Novartis reported positive Phase 3 results for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. Biohaven’s OCD drug troriluzole failed in late-stage trials. Cardinal Health will acquire Solaris Health for $1.9 billion in cash.
13 August 2025
···
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis said two Phase III trials of ianalumab met primary endpoints in Sjögren’s disease, showing significant disease activity reduction. Boehringer Ingelheim’s zongertinib won accelerated FDA approval for HER2-mutant NSCLC. GSK’s gepotidacin received FDA Priority Review for uncomplicated gonorrhea. The U.S. Postal Service began blocking shipments of illicit vaping products amid regulatory scrutiny.
11 August 2025
····
Go toTop